Adamis Pharmaceuticals Corporation ADMP NASDAQ

Adamis Pharmaceuticals Corporation (ADMP) reported total assets of $8.96B and total liabilities of $13.92B for quarter ending 2023-09-30, resulting in total equity of $-4.96B.

The company held $6.66B in cash and short-term investments. Total debt stood at $63.21M, with net debt of $-6.6B. The Debt-to-Equity (D/E) ratio was -0.01 (conservative).

Current ratio is 0.58, which may signal tight short-term liquidity. Interest coverage is -110.8x (weak).

Criteria supported by this page:

• HEALTH (0/100, Fail) — the balance sheet shows elevated risk in debt or liquidity metrics
• MOAT (0/100) — Total assets $8.96B and equity $-4.96B support the company's competitive scale

Overall SharesGrow Score: 10/100 with 0/7 criteria passed.